Design of the Pravastatin or Atorvastatin Evaluation and Infection Therapy (PROVE IT)-TIMI 22 trial

Am J Cardiol. 2002 Apr 1;89(7):860-1. doi: 10.1016/s0002-9149(02)02201-4.
No abstract available

MeSH terms

  • Angina, Unstable / prevention & control
  • Anti-Infective Agents / therapeutic use*
  • Anticholesteremic Agents / therapeutic use*
  • Atorvastatin
  • Chlamydophila Infections / microbiology
  • Chlamydophila Infections / prevention & control*
  • Chlamydophila pneumoniae / drug effects*
  • Cholesterol, LDL / blood*
  • Double-Blind Method
  • Fluoroquinolones*
  • Gatifloxacin
  • Heptanoic Acids / therapeutic use*
  • Humans
  • Hydroxymethylglutaryl-CoA Reductase Inhibitors / therapeutic use
  • Multicenter Studies as Topic
  • Myocardial Infarction / microbiology
  • Myocardial Infarction / prevention & control*
  • Pneumonia, Bacterial / microbiology
  • Pneumonia, Bacterial / prevention & control
  • Pravastatin / therapeutic use*
  • Pyrroles / therapeutic use*
  • Randomized Controlled Trials as Topic
  • Research Design

Substances

  • Anti-Infective Agents
  • Anticholesteremic Agents
  • Cholesterol, LDL
  • Fluoroquinolones
  • Heptanoic Acids
  • Hydroxymethylglutaryl-CoA Reductase Inhibitors
  • Pyrroles
  • Atorvastatin
  • Pravastatin
  • Gatifloxacin